BioCentury | Jul 13, 2015

Baxalta's blueprint

Now that Baxalta Inc. has completed its spinout from Baxter International Inc. , the newco's ambitious plan is to launch 20 new drugs, including line extensions, by 2020. The products, which come from a mix of...
BC Week In Review | Mar 23, 2015
Clinical News

BAX 817: Phase III data

An open-label, international Phase III trial in about 40 male patients ages 12-65 with hemophilia A or B with inhibitors showed that on-demand treatment with 3 IV injections of 90 ug/kg BAX 817 and 1...
BioCentury | Sep 29, 2014

Patient factors

A dearth of options for patients who develop neutralizing antibodies against recombinant blood clotting factor therapies for bleeding disorders was one of the major concerns expressed by patient advocates last week at FDA's patient-focused drug...
Items per page:
1 - 3 of 3